ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 7ÔÂ15ÈÕ£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬±´´ïÒ©ÒµÓëEyePoint¹«Ë¾ÏàÖúÑз¢µÄÒ»¿îÑÛ¿ÆÖÎÁƲúÆ·¡ª¡ªEYP-1901²£Á§ÌåÄÚÖ²Èë¼ÁµÄÐÂ˳Ӧ֢ÁÙ´²ÊÔÑéÉêÇë»ñµÃÅú×¼£¬£¬£¬£¬Ä⿪·¢ÖÎÁƼÈÍù½ÓÊܹý¿¹VEGF²£Á§ÌåÄÚ×¢ÉäµÄʪÐÔ£¨ÐÂÉúѪ¹ÜÐÔ£©ÄêËêÏà¹ØÐԻư߱äÐÔ£¨wAMD£©»¼Õß¡£¡£¡£
2. 7ÔÂ16ÈÕ£¬£¬£¬£¬²©°²ÉúÎïÐû²¼£¬£¬£¬£¬Æä×ÔÖ÷Ñз¢µÄ°¢°ØÎ÷ÆÕÑÛÄÚ×¢ÉäÈÜÒºÉúÎïÀàËÆÒ©£¨BA9101£©µÄÉÏÊÐÉêÇëÒÑ»ñµÃÖйú¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÊÜÀí¡£¡£¡£BA9101Ϊ°¬Á¦ÑŵÄÉúÎïÀàËÆÒ©£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁƳÉÈËÐÂÉúѪ¹Ü£¨ÊªÐÔ£©ÄêËêÏà¹ØÐԻư߱äÐÔ£¨nAMD£©¼°ÌÇÄò²¡ÐԻưßË®Ö×£¨DME£©¡£¡£¡£
3. 7ÔÂ17ÈÕ£¬£¬£¬£¬Á鿵ҩҵÐû²¼Í¨¸æ£¬£¬£¬£¬¹«Ë¾È«×Ê×Ó¹«Ë¾º£ÄÏÁé¿µÖÆÒ©ÓÐÏÞ¹«Ë¾°¬Ë¾°ÂÃÀÀßòþ̼ËáÇâÄÆ¸É»ìÐü¼Á(¢ñ)»ñÅúÁÙ´²£¬£¬£¬£¬ÉêÇëµÄ˳Ӧ֢£ºÎ¸Ê³¹Ü·´Á÷²¡(GERD)-ÒѾÖÎÓúµÄʳ¹ÜÑ×»¼ÕßÔ¤·À¸´·¢µÄºã¾ÃÖÎÁÆ-GERDµÄÖ¢×´¿ØÖÆ;ÐèÒªÒ»Á¬NSAIDÖÎÁƵϼÕß-ÓëʹÓÃ(·ÇçÞÌ忹Ñ×Ò©)NSAIDÖÎÁÆÏà¹ØµÄθÀ£ÑñÖÎÁÆ¡£¡£¡£
1. 7ÔÂ17ÈÕ£¬£¬£¬£¬·øÁª¿Æ¼¼Ðû²¼ÆäÓ뺫¹úÉúÎï¿Æ¼¼¹«Ë¾ SK Biopharmaceuticals Ç©ÊðÁËÒ»Ïî¶ÔÍâÊÚȨÔÊÐíÐÒé¡£¡£¡£Æ¾Ö¤¸ÃÐÒ飬£¬£¬£¬·øÁª¿Æ¼¼ÊÚÓè SK Biopharmaceuticals ¹ØÓÚ FL-091 ·ÅÉäÐÔÒ©ÎïÔÚÈ«Çò¹æÄ£ÄÚ¾ÙÐÐÁÙ´²Ñо¿¡¢¿ª·¢¡¢Éú²úºÍÉÌÒµ»¯µÄ¶À¼ÒȨÁ¦¡£¡£¡£¸ÃÏîÉúÒâ×ܶîΪ 5.715 ÒÚÃÀÔª£¬£¬£¬£¬°üÀ¨Ê׸¶¿î¡¢Ñз¢¼°ÉÌÒµÀï³Ì±®¸¶¿î£¬£¬£¬£¬ÉÐÓÐÌØÐíȨʹÓ÷ÑδÅÌËãÔÚÄÚ¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬¸´µ©´óѧÁ¥ÊôÎ÷ÔÀҽԺëӱ/Ñî»Ô½ÌÊÚÍŶÓÔÚ Journal Of Hematology & Oncology£¨IF = 29.5£©ÉϽÒÏþÁËÌâΪ¡¸Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives¡¹µÄ³¤Æª×ÛÊöÎÄÕ¡£¡£¡£¸Ã×ÛÊö×ܽáÁ˽üÄ꽺ÖÊÁö΢ÇéÐεĶàÖÖÃâÒßµ÷Àí»úÖÆÑо¿Ï£Íû£¬£¬£¬£¬²¢Ì½ÌÖ×îÐÂÕë¶Ô΢ÇéÐÎÃâÒßÒÖÖÆÏà¹ØÏ¸°ûµÄ°ÐÏòÒ©Î↑·¢Ç÷ÊÆºÍÁÙ´²Ñо¿Öص㡣¡£¡£
[1]Lin, H., Liu, C., Hu, A. et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol 17, 31 (2024). https://doi.org/10.1186/s13045-024-01544-7